Search Results

Bunkerhill Contrast AVC is a software device intended for use in detecting presence and estimating quantity of aortic valve calcification for adult patients aged 40 years and above. The device automatically analyzes non-gated, contrast-enhanced chest computed tomography (CT) images collected during clinical care and outputs the region of interest (intended for informational purposes only) and quantification of detected calcium.

The output of the subject device is made available to the physician on-demand as part of his or her standard workflow. The device-generated quantification can be viewed in the patient report at the discretion of the physician, and the physician also has the option of viewing the device- generated calcium region of interest in a diagnostic image viewer. The subject device output in no way replaces the original patient report or the original non-gated, contrast-enhanced CT scan; both are still available to be viewed and used at the discretion of the physician.

The device is intended to provide information to the physician to provide assistance during review of the patient's case. Results of the subject device are not intended to be used on a stand- alone basis and are solely intended to aid and provide information to the physician. In all cases, further action taken on a patient should only come at the recommendation of the physician after further reviewing the patient's results.

Bunkerhill Contrast AVC is a software as a medical device (SaMD) product that interfaces with compatible and commercially available computed tomography (CT) systems. Bunkerhill Contrast AVC detects localizes, and quantifies aortic valve calcification in non-gated, contrast-enhanced chest CT studies. The core features of the product are:

• Detection of aortic valve calcification volume at a threshold of 0 mm³.
• Quantification of the overall aortic valve calcification burden in the form of an estimated volume score (mm³).
• Localization of estimated calcium burden in the form of AVC region of interest applied to a copy of the original CT scan.

The device integrates into the clinician's PACS and does not include a built-in viewer. It works in parallel with and runs in the background of the physician's workflow. When chest CT scans are captured, the images are automatically sent via the DICOM protocol to an on-premises server ("Bunkerhill Edge Server") running the Bunkerhill software. Images are de-identified on the Bunkerhill Edge Server and sent to a Bunkerhill Cloud Server for processing, where the artificial intelligence algorithm (Bunkerhill Contrast AVC) is applied to the image to detect, estimate, and localize aortic valve calcium. The results from the algorithm are then relayed back to the on-premises Bunkerhill Edge Server, where the associated chest CT images are re-identified, and results are paired with the appropriate images and routed to be made available in the physician's workflow.

Here's a breakdown of the acceptance criteria and study details for the Bunkerhill Contrast AVC device, based on the provided FDA 510(k) Clearance Letter:

Bunkerhill Contrast AVC Study Analysis

1. Table of Acceptance Criteria and Reported Device Performance

2. Sample Size and Data Provenance for Test Set

• Pivotal Study:
  • Sample Size: Not explicitly stated. The text mentions the dataset was "curated from multiple sites across three geographical regions in the United States."
  • Data Provenance: Multiple sites across three geographical regions in the United States. Retrospective.
• Bridging Study:
  • Sample Size: 65 cases.
  • Data Provenance: Not explicitly stated, but "comparing the volume generated by the Contrast AVC device on a contrast-enhanced image to the calcification volume on the same patient calculated on a non-contrast image." Implies retrospective data from patients who underwent both types of scans.

3. Number of Experts and Qualifications for Ground Truth

• Number of Experts: Not specified.
• Qualifications of Experts: Not specified. The acceptance criteria for the pivotal study's agreement metrics (bias, LOA) were derived from "clinical literature in high impact journals that investigate the inter-reader agreement of manual segmentation," implying expert-based ground truth.

4. Adjudication Method for Test Set

• Adjudication Method: Not explicitly stated. The reliance on "inter-reader agreement of manual segmentation" from clinical literature suggests that the ground truth methodology likely involved multiple readers, but the specific adjudication method (e.g., 2+1, 3+1) is not detailed.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

• Was an MRMC study done? No. The studies described are standalone performance evaluations of the algorithm, not comparative effectiveness studies with or without AI assistance for human readers.

6. Standalone Performance

• Was a standalone study done? Yes. Both the pivotal study and the bridging study evaluated the "Contrast AVC device" performance in a "stand-alone retrospective study" for "detection, localization and agreement of the device output compared to the established ground truth."

7. Type of Ground Truth Used

• Pivotal Study: Implied to be expert consensus or manual segmentation by experts, given the reference to "inter-reader agreement of manual segmentation" in clinical literature.
• Bridging Study: Ground truth was established by "calcification volume on the same patient calculated on a non-contrast image" — which itself would have been established by a ground truth methodology (likely expert manual segmentation) for the non-contrast images.

8. Sample Size for Training Set

• Sample Size: Not provided in the document.

9. How the Ground Truth for the Training Set Was Established

• Ground Truth Establishment: Not provided in the document. However, for a deep learning model, it would typically involve expert manual annotation or segmentation of calcifications on a large dataset of CT images.

Ask a specific question about this device

Bunkerhill Contrast CAC is a software device intended for use in detecting presence and estimating quantity of coronary artery calcification for adult patients aged 30 years and above. The device automatically analyzes non-gated, contrast-enhanced chest computed tomography (CT) images collected during clinical care and outputs the region of interest (intended for informational purposes only) and quantification of detected calcium.

The output of the subject device is made available to the physician on-demand as part of his or her standard workflow. The device-generated quantification can be viewed in the patient report at the discretion of the physician, and the physician also has the option of viewing the device-generated calcium region of interest in a diagnostic image viewer. The subject device output in no way replaces the original patient report or the original non-gated, contrast-enhanced CT scan; both are still available to be viewed and used at the discretion of the physician.

The device is intended to provide information to the physician to provide assistance during review of the patient's case. Results of the subject device are not intended to be used on a stand-alone basis and are solely intended to aid and provide information to the physician. In all cases, further action taken on a patient should only come at the recommendation of the physician after further reviewing the patient's results.

Bunkerhill Contrast CAC is a software as a medical device (SaMD) product that interfaces with compatible and commercially available computed tomography (CT) systems. Bunkerhill Contrast CAC detects, localizes, and quantifies coronary artery calcification volume in non-gated, contrast-enhanced chest CT studies. The core features of the product are:

• Detection of coronary artery calcification volume at a threshold of 0 mm³.
• Quantification of the overall coronary artery calcification burden in the form of an estimated volume score.
• Localization of estimated calcium burden in the form of a CAC region of interest applied to a copy of the original CT scan.

Here's a breakdown of the acceptance criteria and study details for the Bunkerhill Contrast CAC device, based on the provided FDA 510(k) clearance letter:

Acceptance Criteria and Reported Device Performance

Study Details

1. Sample Size Used for the Test Set and Data Provenance:

   • Test Set Sample Size: The exact number of cases in the "pivotal dataset" is not explicitly stated. It mentions the dataset was "curated from multiple sites across three geographical regions in the United States."
   • Data Provenance: Retrospective, from "multiple sites across three geographical regions in the United States."

2. Number of Experts Used for Ground Truth and Qualifications:

   • The document states that acceptance criteria were "derived from the performance of the predicate device and clinical literature in high impact journals that investigate the inter-reader agreement of manual segmentation." It does not explicitly state the number or qualifications of experts used to establish the ground truth for the test set.

3. Adjudication Method for the Test Set:

   • The document does not explicitly state an adjudication method (e.g., 2+1, 3+1). It refers to the "established ground truth."

4. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study:

   • Not explicitly stated. The document describes a "stand-alone retrospective study for detection, localization and agreement of the device output compared to the established ground truth," and mentions that results "are not intended to be used on a stand-alone basis and are solely intended to aid and provide information to the physician." This implies a focus on standalone performance against ground truth rather than a comparative effectiveness study with human readers.

5. Standalone Performance:

   • Yes, a standalone study was done. The document states, "The Contrast CAC performance was validated in a stand-alone retrospective study for detection, localization and agreement of the device output compared to the established ground truth."

6. Type of Ground Truth Used:

   • The type of ground truth is not explicitly specified as "expert consensus," "pathology," or "outcomes data." However, the statement that acceptance criteria were "derived from... clinical literature in high impact journals that investigate the inter-reader agreement of manual segmentation" strongly suggests that the ground truth was established through expert manual segmentation or review, potentially leading to an expert consensus, on the coronary artery calcification volume.

7. Sample Size for the Training Set:

   • The document does not state the sample size for the training set.

8. How Ground Truth for the Training Set Was Established:

   • The document does not explicitly describe how the ground truth for the training set was established. It only mentions that the device uses "deep-learning algorithms," which implies a training phase with labeled data.

Ask a specific question about this device

Bunkerhill MAC is a software device intended for use in detecting presence and estimating quantity of mitral annulus calcification for adult patients aged 40 years and above. The device automatically analyzes non-gated, non-contrast chest computed tomography (CT) images collected during clinical care and outputs the region of interest (intended for informational purposes only) and quantification of detected calcium.

The device-generated quantification can be viewed in the patient report at the discretion of the physician, and the physician also has the option of viewing the device-generated calcium region of interest in a diagnostic image viewer. The subject device output in no way replaces the original patient report or the original non-gated, non-contrast CT scan; both are still available to be viewed and used at the discretion of the physician.

The device is intended to provide information to the physician to provide assistance during review of the patient's case. Results of the subject device are not intended to be used on a stand-alone basis and are solely intended to aid and provide information to the physician. In all cases, further action taken on a patient should only come at the recommendation of the physician after further reviewing the patient's results.

Bunkerhill MAC is a software as a medical device (SaMD) product that interfaces with compatible and commercially available computed tomography (CT) systems. Bunkerhill MAC detects, localizes, and quantifies mitral annulus calcification in non-gated, non-contrast chest CT studies. The core features of the product are:

• Detection of mitral annulus calcification at an Agatston-equivalent score threshold of 0 AU.
• Quantification of the overall mitral annulus calcification burden in the form of an estimated Agatston Score up to 5000 Agatston-equivalent units
• Localization of estimated calcium burden in the form of circular region of interest applied to a copy of the original CT scan.

Here's a detailed breakdown of the acceptance criteria and the study proving the Bunkerhill MAC device meets them, based on the provided FDA 510(k) clearance letter:

Acceptance Criteria and Reported Device Performance

Study Details

1. Sample Size used for the test set and the data provenance:

   • Test Set Sample Size: Not explicitly stated as a number of cases, but referred to as "the pivotal dataset."
   • Data Provenance: "curated from multiple sites across three geographical regions in the United States." (Retrospective study).

2. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

   • The document states "agreement of the device output compared to the established reference standard." It does not explicitly state the number of experts used or their qualifications for establishing this "established reference standard." It only refers to "clinical literature in high impact journals that investigate the inter-reader agreement of manual segmentation" as informing the acceptance criteria.

3. Adjudication method for the test set:

   • The document does not explicitly state an adjudication method (e.g., 2+1, 3+1) for establishing the ground truth of the test set. It refers to an "established reference standard."

4. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

   • No, a multi-reader multi-case (MRMC) comparative effectiveness study comparing human readers with AI assistance versus human readers without AI assistance was not conducted or reported in this document. The study was a "stand-alone retrospective study for detection, localization and agreement of the device output compared to the established reference standard."

5. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:

   • Yes, a standalone study was performed. The document explicitly states: "The Bunkerhill MAC performance was validated in a stand-alone retrospective study for detection, localization and agreement of the device output compared to the established reference standard."

6. The type of ground truth used:

   • The ground truth was an "established reference standard" which was used for comparison against the device's output. The document implies this reference standard is based on non-gated CT reference measurements and potentially "manual segmentation" informed by clinical literature. It does not explicitly state pathology confirmation or direct outcomes data as the primary ground truth.

7. The sample size for the training set:

   • The sample size for the training set is not provided in the document.

8. How the ground truth for the training set was established:

   • The document does not provide information on how the ground truth for the training set was established. It only refers to the performance validation on a "pivotal dataset" (test set).

Ask a specific question about this device

Bunkerhill ECG-EF is software intended to aid in screening for Left Ventricular Ejection Fraction (LVEF) less than or equal to 40% in adults at risk for, but not already diagnosed with low LVEF.

Bunkerhill ECG-EF is not intended to be a stand-alone diagnostic device for cardiac conditions, should not be used for monitoring of patients, and should not be used on ECGs with a paced rhythm. A positive result may suggest the need for further clinical evaluation in order to establish a diagnosis of Left Ventricular Ejection Fraction (LVEF) less than or equal to 40%.

Additionally, if the patient is at high risk for the cardiac condition, a negative result should not rule out further non-invasive evaluation.

Bunkerhill ECG-EF is adjunctive and must be interpreted in conjunction with the clinician's judgment, the patient's medical history, symptoms, and additional diagnostic tests. For a final clinical diagnosis, further confirmatory testing, such as echocardiography, is required.

ECG-EF is a software-only medical device that employs deep learning algorithms to analyze 12-lead ECG data for the detection of low left ventricular ejection fraction (LVEF < 40%). The algorithm processes 10-second ECG waveform snippets, providing predictions to assist healthcare professionals in the early identification of patients at risk for heart failure.

ECG-EF algorithm receives digital 12-lead ECG data and processes it through its machine learning model. The output of the analysis is transmitted to integrated third-party software systems, such as Electronic Medical Records (EMR) or ECG Management Systems (EMS). The results are displayed by the third-party software on a device such as a smartphone, tablet, or PC.

ECG-EF algorithm produces a result indicating "Low EF Screen Positive - High probability of low ejection fraction based on the ECG", " Low EF Screen Negative - Low probability of low ejection fraction based on the ECG" or "Error – device input criteria not met " for cases that do not meet data input requirements. These results are not intended to be definitive diagnostic outputs but rather serve as adjunctive information to support clinical decision-making. A disclaimer accompanies the output, stating: "Not for diagnostic use. The results are not final and must be reviewed alongside clinical judgment and other diagnostic methods."

The Low Ejection Fraction AI-ECG Algorithm device is intended to address the unmet need for a point-of-care screen for LVEF less than or equal to 40% and is expected to be used by cardiologists, front-line clinicians at primary care, urgent care, and emergency care settings, where cardiac imaging may not be available or may be difficult or unreliable for clinicians to operate. Clinicians will use the Low Ejection Fraction AI-ECG Algorithm to aid in screening for LVEF less than or equal to 40% and making a decision for further cardiac evaluation.

Here's a breakdown of the acceptance criteria and the study details for the Bunkerhill ECG-EF device, based on the provided FDA 510(k) Clearance Letter:

1. Table of Acceptance Criteria and Reported Device Performance

2. Sample Size for the Test Set and Data Provenance

• Sample Size for Test Set: 15,994 patient records.
• Data Provenance:
  • Country of Origin: United States.
  • Source: Two health systems.
  • Type: Retrospective study.
  • Diversity: Representative of the U.S. population (65.5% White, 18.8% Hispanic, 5.7% American Indian or Alaska Native, 3.9% Asian, 3.0% Black/African American, 2.8% Other; 53% Male, 47% Female).
  • Geographical Distribution: Curated from 5 geographically distributed sites throughout the United States.

3. Number of Experts and Qualifications for Ground Truth

The document does not explicitly state the number of experts used or their specific qualifications for establishing the ground truth. It only mentions that the ground truth was established from echocardiograms.

4. Adjudication Method for the Test Set

The document does not specify an adjudication method (e.g., 2+1, 3+1, none) for the test set. The ground truth was derived directly from echocardiogram measurements.

5. MRMC Comparative Effectiveness Study

The document does not mention a Multi-Reader Multi-Case (MRMC) comparative effectiveness study or any effect size of human readers improving with AI vs. without AI assistance. The study focuses solely on the standalone performance of the AI algorithm.

6. Standalone Performance Study (Algorithm Only)

Yes, a standalone study evaluating the algorithm's performance without human-in-the-loop was conducted. The performance metrics (Sensitivity, Specificity, PPV, NPV) and the confusion matrix presented are for the algorithm's direct output.

7. Type of Ground Truth Used

The ground truth used was Transthoracic Echocardiogram (TTE) with disease, specifically using the Simpson's Biplane measurement method to determine Left Ventricular Ejection Fraction (LVEF) less than or equal to 40%. The echocardiogram was taken less than 15 days apart from the ECG scan.

8. Sample Size for the Training Set

The document does not explicitly state the sample size used for the training set. It only mentions the retrospective study for validation involved 15,994 patient records.

9. How Ground Truth for the Training Set Was Established

The document states that the "Ground Truth for Model Training" was Transthoracic echocardiogram (TTE) with disease. It can be inferred that this same method (TTE, likely Simpson's Biplane) was used to establish ground truth for the training data, similar to the test set, but specific details on the process for the training set are not provided.

Ask a specific question about this device

Bunkerhill AAQ is a radiological image processing system software indicated for use in the analysis of CT exams with or without contrast, that include the L1 – L5 region of the abdominal aorta, in adults aged 22 and older.

The device is intended to assist appropriately trained medical specialists by providing the user with the maximum axial abdominal aortic diameter measurement of cases that include the abdominal aorta. Bunkerhill AAQ is indicated to evaluate normal and aneurysmal abdominal aortas and is not intended to evaluate post-operative aortas.

The Bunkerhill AAQ results are not intended to be used on a stand-alone basis for clinical decision-making or otherwise preclude clinical assessment of cases. These measurements are unofficial, are not final, and are subject to change after review by a qualified interpreting physician. For final clinically approved measurements, please refer to the official radiology report. Clinicians are responsible for viewing full images per the standard of care.

Bunkerhill AAQ is a software-only medical device that employs deep learning algorithms to provide automatic maximal abdominal aortic diameter measurements from axial CT scans of the abdomen/pelvis, with or without IV contrast.

Bunkerhill AAQ receives DICOM instances and processes them chronologically by running the algorithm on relevant series to measure the maximum abdominal aortic diameter. Following the AI processing, the output of the algorithm analysis is transferred to standard radiology image review and reporting software.

Bunkerhill AAQ produces a preview image annotated with the maximum axial diameter measurement. The diameter marking is not intended to be a final output, but serves the purpose of visualization and measurement. The original, unmarked series remains available in the PACS as well.

The preview image presents an unofficial and not final measurement, and the user is instructed to review the full image and any other clinical information before making a clinical decision. The image includes a disclaimer: "Not for diagnostic use. The measurement is unofficial, not final, and must be reviewed by a qualified interpreting physician".

Here's a breakdown of the acceptance criteria and the study proving the device meets those criteria, based on the provided FDA 510(k) clearance letter for Bunkerhill Abdominal Aortic Quantification (AAQ):

1. Table of Acceptance Criteria and Reported Device Performance

2. Sample Size Used for the Test Set and Data Provenance

• Test Set Sample Size: 258 patients
• Data Provenance: Retrospective study. Data sourced from North Carolina, Alabama, the greater Washington D.C. area (all in the USA), and Sao Paulo, Brazil. This indicates a diverse geographical origin for the data.

3. Number of Experts Used to Establish Ground Truth for the Test Set and Their Qualifications

• Number of Experts: 3
• Qualifications of Experts: U.S. Board Certified Radiologists. Specific experience level (e.g., 10 years) is not provided, but Board Certification implies a high level of expertise.

4. Adjudication Method for the Test Set

• The text states "a ground truth established by 3 U.S. Board Certified Radiologists." This implies a consensus-based approach among the three experts to establish the definitive ground truth reference. The specific adjudication method (e.g., majority vote, discussion to reach consensus) is not detailed, but the use of three experts suggests a robust process beyond a single reader.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done

• No, an MRMC comparative effectiveness study involving human readers with vs. without AI assistance was not reported. The study described is a standalone performance study of the algorithm against a defined ground truth.

6. If a Standalone (Algorithm Only Without Human-in-the-Loop Performance) Was Done

• Yes, a standalone performance study was done. The text explicitly states, "The AAQ algorithm performance was validated in a stand-alone retrospective study for overall agreement of the device output compared to a ground truth established by 3 U.S. Board Certified Radiologists." The results (MAE, ΔICC, Bland-Altman limits) are all reflective of the algorithm's performance in isolation.

7. The Type of Ground Truth Used

• Expert Consensus. The ground truth was "established by 3 U.S. Board Certified Radiologists," indicating that their consensus measurements were considered the true values for comparison.

8. The Sample Size for the Training Set

• Not provided. The document only references the test set of 258 patients. Information regarding the training set size is not included in this excerpt.

9. How the Ground Truth for the Training Set Was Established

• Not provided. Since the training set size itself is not mentioned, the method for establishing its ground truth is also absent from this document. It's common practice for similar methods (e.g., expert annotations) to be used for training data, but this specific excerpt doesn't confirm it.

Ask a specific question about this device

The Bunkerhill BMD Algorithm is a post-processing AI-powered software intended for adults 30 years and above to assess estimated DXA-measured average areal bone mineral density of spinal bones from existing CT scans and outputs a flag for low bone density below a pre-specified threshold. It is not intended to replace DXA or any other tests dedicated to BMD measurement.

Bunkerhill BMD is an opportunistic AI-powered tool that enables:(1) retrospective assessment of bone density from CT scans acquired for other purposes, (2) assessment of bone density in conjunction with another medically appropriate procedure involving CT scans, and (3) assessment of bone density without a phantom as an independent measurement procedure

The Bunkerhill BMD application is a software only medical device (SaMD) that includes deep- learning-based computer vision and post-processing algorithms that estimates the bone mineral density from previously obtained computed tomography (CT) images.

The results from Bunkerhill BMD are not intended to be used as the primary input for clinical decision making, but rather are intended to provide information that may assist the clinician to identify 'findings of interest' within existing imaging studies.

Here's a breakdown of the acceptance criteria and study details for the BunkerHill BMD device, based on the provided FDA 510(k) clearance letter:

Acceptance Criteria and Device Performance Study for BunkerHill BMD

1. Table of Acceptance Criteria and Reported Device Performance

2. Sample Size and Data Provenance for the Test Set

• Test Set Sample Size: 371 CT studies
• Data Provenance: The studies were collected from four (4) geographically diverse sites. The retrospective nature of the study is explicitly stated ("stand-alone retrospective study").

3. Number of Experts and Qualifications for Ground Truth

The document does not explicitly state the number of experts used to establish the ground truth or their specific qualifications (e.g., "radiologist with 10 years of experience").

4. Adjudication Method for the Test Set

The document does not explicitly state the adjudication method (e.g., 2+1, 3+1, none) used for the test set.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

No, an MRMC comparative effectiveness study involving human readers with and without AI assistance was not reported in the provided text. The study described is a standalone performance evaluation of the algorithm.

6. Standalone Performance Study

Yes, a standalone (algorithm only without human-in-the-loop performance) study was done. The document states: "Bunkerhill BMD performance was validated in a stand-alone retrospective study for overall agreement of the device output compared to the established ground truth."

7. Type of Ground Truth Used

The type of ground truth used is implied to be based on DXA-measured average areal bone mineral density of spinal bones, as the device is intended to "assess estimated DXA-measured average areal bone mineral density." The text refers to "established ground truth" in relation to this assessment.

8. Sample Size for the Training Set

The document does not provide the sample size for the training set. It only describes the test set.

9. How the Ground Truth for the Training Set Was Established

The document does not provide information on how the ground truth for the training set was established. It only refers to "established ground truth" for the test set evaluation.

Ask a specific question about this device

Bunkerhill AVC is a software device intended for use in detecting presence and estimating quantity of aortic valve calcification for adult patients aged 40 years and above. The device automatically analyzes non-gated, non-contrast chest computed tomography (CT) images collected during clinical care and outputs the region of interest (intended for informational purposes only) and quantification of detected calcium.

The output of the subject device is made available to the physician on-demand as part of his or her standard workflow. The device-generated quantification can be viewed in the patient report at the discretion of the physician, and the physician also has the option of viewing the device-generated calcium region of interest in a diagnostic image viewer. The subject device output in no way replaces the original patient report or the original non-gated, non-contrast CT scan; both are still available to be viewed and used at the discretion of the physician.

The device is intended to provide information to the physician to provide assistance during review of the patient's case. Results of the subject device are not intended to be used on a stand-alone basis and are solely intended to aid and provide information to the physician. In all cases, further action taken on a patient should only come at the recommendation of the physician after further reviewing the patient's results.

Bunkerhill AVC is a software as a medical device (SaMD) product that interfaces with compatible and commercially available computed tomography (CT) systems. Bunkerhill AVC detects, localizes, and quantifies aortic valve calcification in non-gated, non-contrast chest CT studies. The core features of the product are:

• Detection of aortic valve calcification at an Agatston-equivalent score threshold of 0 AU. •
• . Estimation of the overall aortic valve calcification burden in the form of an estimated Agatston-equivalent Score.
• Localization of estimated calcium burden in the form of AVC region of interest applied . to a copy of the original CT scan.

Here's a breakdown of the acceptance criteria and the study that proves the device meets them, based on the provided text:

1. A table of acceptance criteria and the reported device performance

The provided text describes specific performance metrics that were evaluated, although it doesn't explicitly present a formal "acceptance criteria table" with target values. Instead, it describes how the device's observed performance met the acceptance criteria.

Notes on Acceptance Criteria: The document states that "The acceptance criteria were derived from the performance of the predicate device and clinical literature in high impact journals that inter-reader agreement of manual segmentation." This indicates a benchmark against established clinical practice and a comparable device.

2. Sample sized used for the test set and the data provenance

• Sample Size for Test Set: Not explicitly stated as a numerical count of patients or cases. However, the data for the pivotal study was "curated from thirty-three (33) sites."
• Data Provenance:
  • Country of Origin: United States ("thirty-three (33) sites across three geographical regions in the United States").
  • Retrospective or Prospective: Retrospective ("standalone retrospective study").

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

The document does not provide information on the number or qualifications of experts used to establish the ground truth for the test set. It only mentions that the ground truth was "established."

4. Adjudication method for the test set

The document does not specify any adjudication method (e.g., 2+1, 3+1, none) used for the test set.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

A multi-reader multi-case (MRMC) comparative effectiveness study assessing human reader improvement with AI assistance was not conducted or reported. The study described is a "standalone retrospective study for localization and agreement of the device output compared to the established ground truth." The device is intended as an "adjunctive information" tool, not a human-in-the-loop performance enhancer for diagnostic accuracy per se, but rather an aid for quantifying calcification.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

Yes, a standalone study was done. The text explicitly states: "The Bunkerhill AVC performance was validated in a stand-alone retrospective study for localization and agreement of the device output compared to the established ground truth."

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)

The type of ground truth used was "established ground truth." While this term is somewhat generic, given the context of Agatston-equivalent scores and "inter-reader agreement of manual segmentation" mentioned for acceptance criteria, it strongly implies ground truth established by expert (likely radiologist or cardiologist) review and manual measurement/segmentation. It is not stated to be pathology or outcomes data.

8. The sample size for the training set

The document does not provide the sample size for the training set. It only discusses the pivotal test set.

9. How the ground truth for the training set was established

The document does not provide information on how the ground truth for the training set was established.

Ask a specific question about this device

Bunny Wax Personal Lubricant is a personal lubricant indicated for penile and/or vaginal application intended to lubricate and enhance the ease and comfort of intimate sexual activity and supplement the body's natural lubrication. This product is compatible with natural rubber latex, polyurethane, and polyisoprene condoms.

Not Found

I am sorry, but the provided text is a letter from the FDA regarding the substantial equivalence determination for a medical device (Bunny Wax Personal Lubricant). It does not contain information about acceptance criteria, a specific study proving the device meets those criteria, or details regarding AI/ML algorithm performance.

Therefore, I cannot extract the requested information to fill in the table or answer the specific questions about a study and AI/ML performance. The document focuses on regulatory approval based on equivalence to predicate devices, not on performance metrics of an AI system.

Ask a specific question about this device

The Bunegin-Albin Air Aspiration Set is intended to aspirate venous air emboli.

The Bunegin-Albin Air Aspiration Set is comprised of an air aspiration catheter, wire guide, entry access needle, dilator, syringe, stopcock, and scalpel. The air aspiration catheter is manufactured from radiopaque extruded polyethylene tubing and is designed with a pre-molded winged fitting. The catheter is 5.8 French in size with an endhole diameter of 0.035 inches. The wire guide is manufactured from stainless steel coils, a safety wire, and a mandril wire. The access needle is manufactured from stainless steel. The dilator is manufactured from polyethylene and has a pre-molded proximal hub. The set also includes a 12 cc syringe, a low pressure three way stopcock, and a scalpel. The Bunegin-Albin Air Aspiration Set is sterilized by ethylene oxide and intended for one-time use.

This documentation outlines the acceptance criteria and the results of various studies conducted for the Bunegin-Albin Air Aspiration Set to demonstrate its performance and substantial equivalence to a predicate device.

1. Table of Acceptance Criteria and Reported Device Performance

2. Sample Size Used for the Test Set and Data Provenance

The document does not explicitly state the specific numerical sample sizes for each physical and chemical test (e.g., Catheter Shaft Tensile, Wire Guide Corrosion). Instead, the document refers to compliance with international standards (e.g., BS EN ISO 10555-1, BS EN ISO 11070, ISO 594-2, BS EN 13868, USP 788) which would implicitly define sample sizes for such tests.

For the Animal Testing, a specific sample size is not stated, but the testing evaluated the "acute performance" in an animal model. The provenance would be experimental ("prospective" if considered in the context of device development) rather than clinical human data. The country of origin for the animal study is not specified in the provided text.

The data for all engineering performance and biocompatibility tests is based on prospective testing conducted specifically for this device submission to demonstrate compliance with standards and design input requirements. The country of origin of this testing data is not explicitly stated, but it is for a device manufactured by Cook Incorporated, presumably in the US or one of their international facilities.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications

For the engineering performance tests (tensile strength, kink resistance, leakage, etc.) and particulate testing, "ground truth" is established by adherence to quantitative specifications defined by international standards (e.g., ≥ 15 N, no air entry, no liquid leak, USP 788 thresholds). Therefore, these do not rely on human expert consensus in the same way clinical image interpretation might. The "experts" in this context would be the technicians and engineers performing and verifying the tests against the defined standards.

For Animal Testing, the grading of "adequate" or "good" for performance parameters and ability to remove air would imply evaluation by experts, likely veterinary surgeons or researchers with expertise in animal models and medical device performance. The number and specific qualifications of these experts are not provided.

For Biocompatibility testing, "ground truth" is established by the results of standardized tests per ISO 10993-1 and FDA guidance. Experts would be toxicologists and other scientific professionals interpreting these results, but their number and specific qualifications are not detailed.

4. Adjudication Method for the Test Set

For the physical, chemical, and mechanical performance tests, the adjudication method is direct comparison of measured values against predefined numerical or qualitative acceptance criteria outlined in international standards. There is no mention of a human consensus or specific adjudication for these quantitative evaluations beyond meeting the standard.

For the Animal Testing, the "grading of 'adequate' or 'good'" suggests an assessment, but the specific adjudication method (e.g., single expert, 2+1 consensus) is not detailed.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

No MRMC comparative effectiveness study was done. The device is a physical medical instrument (an air aspiration set), not an AI or imaging diagnostic device that would typically involve human readers interpreting cases.

6. Standalone (Algorithm Only Without Human-in-the-Loop Performance) Study

Not applicable as this is a physical medical device. The "performance" studies are standalone in the sense that they evaluate the device's physical properties and functionality without human intervention being part of the device's performance mechanism, but rather as the operators and evaluators of the device.

7. Type of Ground Truth Used

The ground truth for the various tests is established through a combination of:

• International Standards and Specifications: For most physical, mechanical, and chemical tests (tensile strength, kink length, leakage, particulate counts, etc.), the ground truth is defined by the acceptance criteria set forth in specific ISO and BS EN standards (e.g., BS EN ISO 10555-1, BS EN ISO 11070, ISO 594-2, BS EN 13868, USP 788 thresholds).
• Empirical Observation/Expert Assessment: For animal testing, the ground truth is based on the observed "adequate" or "good" performance and the ability to remove air from target sites, likely evaluated by trained personnel.
• Biocompatibility Standards: For biocompatibility, the ground truth is compliance with the requirements of ISO 10993-1 and FDA guidance, demonstrated through specific laboratory test results.

8. Sample Size for the Training Set

Not applicable in the context of device performance testing for substantial equivalence. There is no mention of a "training set" as this device does not involve machine learning or AI algorithms requiring data for training. The studies described are for verification and validation of the manufactured product.

9. How the Ground Truth for the Training Set was Established

Not applicable, as there is no training set for this type of device.

Ask a specific question about this device

LPV II Valves and Kits
The Standard-LPV II and Mini-LPV II Valves, utilized in the treatment of hydrocephalic patients in systems designed to shunt cerebrospinal fluid from the lateral ventricles of the brain into either the right atrium of the heart or the peritoneum. The Mini-LPV II Valve can be used in (but is not restricted to) situations where skin erosion may be a problem, as with older patients.

Novus Valves and Kits
The Novus and Novus Mini Valves, utilized in the treatment of hydrocephalic patients, are components in systems designed to shunt cerebrospinal fluid from the lateral ventricles of the right atrium of the heart or the peritoneum. The Novus Mini Valve can be used in (but is not restricted to) situations where skin erosion may be a problem, as with older patients. Valves with a Physiological Flow Device are intended to reduce the hazard of negative intraventricular pressure (with respect to atmospheric pressure) when the patient is sitting, standing or semi-recumbent.

Multi-Purpose Valve
The Multi-Purpose Valve, utilized in the treatment of hydrocephalic patients, is a component in systems designed to shunt cerebrospinal fluid from the lateral ventricles into either the right atrium of the heart or the perioneum. Valves with an Anti-Siphon Device are intended to reduce the hazard of negative intraventricular pressure when the patient is sitting, semi-recumbent or standing.

Mishler Dual Chamber Valve with Integral Connectors
The Mishler Dual Chamber Flushing Valve, Flat Bottom Design, utilized in the treatment of hydrocephalic patients, is a component in systems designed to shunt cerebrospinal fluid from the lateral ventricles into either the right atrium of the heart or the peritoneum. Valves with an Anti-Siphon Device are intended to reduce the hazard of negative intraventricular pressure when the patient is sitting, semi-recumbent or standing.

Pudenz Flushing Valve with Integral Connectors
The Pudenz Flushing Valve, utilized in the treatment of hydrocephalic patients, is a component in systems designed to shunt cerebrospinal fluid from the lateral ventricles of the brain into either the right atrium of the heart or the peritoneum. Valves with an Anti-Siphon Device are intended to reduce the intraventricular pressure when the patient is sitting, semi-recumbent or standing.

Ultra VS In-Line Valve System
The Ultra VS In-Line Valves, utilized in the treatment of hydrocephalic patients, are components in systems designed to shunt cerebrospinal fluid (CSF) from the lateral ventricles into either the peritoneal cavity or the right atrium of the heart. The in-line and burr-hole systems are designed to shunt cerebrospinal fluid from the lateral ventricles into the peritoneal cavity. A ventriculoperitoneal shunting system may be indicated to avoid the cardiovascular complications of an atrial shunt or for a hydrocephalic patient in whom an atrial shunt is contraindicated. The Small and Neonate Models can be used in (but are not restricted to) situations where skin erosion may be a problem, as with premature infants, pediatric patients and older patients.

Pudenz Cardiac and Infant Catheter
The Pudenz Cardiac Catheter, utilized in the treatment of hydrocephalic patients, is a component in systems designed to shunt cerebrospinal fluid from the lateral ventricles of the right atrium of the heart. The Infant Cardiac Catheter is utilized when the common facial and/or internal jugular veins are too small to accommodate the larger cardiac catheter.

Pudenz Ventricular Catheter
The Pudenz Ventricular Catheter, utilized in the treatment of hydrocephalic patients, is a component in systems designed to shunt cerebrospinal fluid from the lateral ventricles of the right atrium of the heart or the peritoneum.

Pudenz Peritoneal Catheter
The Pudenz Peritoneal Catheter, utilized in the treatment of hydrocephalic patients, is a component in systems designed to shunt cerebrospinal fluid from the lateral ventriculoperitoneum. A ventriculoperitoneal shunting system may be indicated to avoid the cardiovascular complications of an atrial shunt or for a hydrocephalic patient in whom an atrial shunt is contraindicated.

Peritoneal Reflux Control Catheter and Peritoneal Open-Ended Catheter With Slits
The Peritoneal Reflux Control Catheter and Peritoneal Open-Ended Catheter with Slits, utilized in the treatment of hydrocephalic patients, are components for systems designed to shunt cerebrospinal fluid from the lateral ventricles into the peritoneum. A ventriculoperitoneal shunting system may be indicated to avoid the cardiovascular complications of an atrial shunt or for a hydrocephalic patient in whom an atrial shunt is contraindicated.

Portnoy Ventricular Catheter
The Portnoy Ventricular Catheter, utilized in the treatments, is a component in systems designed to shunt cerebrospinal fluid from the lateral ventricles into either the right atrium of the heart or the peritoneum.

Neuroview Endoscopic Ventricular Catheter
The Neuroview Ventricular Catheter, utilized in the treatment of hydrocephalic patients, is a component in systems designed to shunt cerebrospinal fluid from the lateral ventricles into either the right atrium of the heart or the peritoneum.

Integra CSF Reservoir with Integral Connectors
The Integra CSF Reservoir provides access to the lateral cerebral ventricles via hypodermic puncture for sampling and/or injection of fluids. It is useful in obtaining CSF samples for cytological and chemical studies, for monitoring ventricular fluid pressure and for ventricular drainage. The Convertible Integra CSF Reservoir may be utilized in hydrocephalic patients as a component in systems designed to shunt CSF from the lateral ventricles into either the right atrium of the heart or the peritoneum.

Essential Shunt Kit Burr Hole Design
The CSF Control Valve, utilized in the treatments, is a component in systems designed to shunt cerebrospinal fluid from the lateral ventricles of the right atrium of the heart or the peritoneum.

Essential Shunt Kit Flat Bottom Design
The Essential Shunt Kit – Flat Bottom Design, utilized in the treatment of hydrocephalic patients, is designed to shunt cerebrospinal fluid from the lateral ventricles of the brain into the peritoneum. The Essential Shunt Kit – Flat Bottom Design, can be used in (but is not restricted to) situations where skin erosion may be a problem, as with older patients.

Connectors for Neurosurgical Use
Integra connectors are utilized principally in the treatment of hydrocephalic patients, as components in systems designed to shunt cerebrospinal fluid from the lateral cerebral ventricles of the right atrium of the heart or the peritoneum.

On-Off Flushing Reservoirs
The On-Off Flushing Reservoir, utilized in the treatment of hydrocephalic patients, is a component in systems designed to shunt cerebrospinal fluid from the lateral ventricles into either the right atrium of the peritoneum. Reservoirs with an Anti-Siphon Device are intended to reduce the hazard of negative intraventricular pressure when the patient is sitting, semi-recumbent or standing.

Braden Flushing Reservoir
The Braden Flushing Reservoir, utilized in the treatment of hydrocephalic patients, is a component in systems designed to shunt cerebrospinal fluid from the lateral ventricles into either the right atrium of the heart or the peritoneum.

Foltz Flushing Reservoir
The Foltz Flushing Reservoir, utilized in the treatment of hydrocephalic patients, is a component in systems designed to shunt cerebrospinal fluid from the lateral ventricles into either the right atrium of the heart or the peritoneum.

Anti-Siphon Device
The Anti-Siphon Device, utilized in the treatment of hydrocephalic patients, is a component in systems designed to shunt cerebrospinal fluid from the lateral ventricles of the right atrium of the heart or the heart or the peritoneum. The device is designed to reduce the potential hazards of excessive lowering of intraventricular pressure (with respect to atmospheric pressure) when the patient is in a sitting, standing or erect position.

Integra Neurological Shunts and Accessories are used in the treatment of hydrocephalus. Hydrocephalus is commonly treated by creating a CSF flow pathway from a cerebral ventricle to the peritoneal spaces in the abdomen or to the right atrium of the heart. This is commonly referred to as "shunting". Integra markets a full line of products for CSF shunting procedures including catheters, valves, reservoir devices, connectors and accessories to aid in implantation.

A shunt system may comprise of a catheter, valve, reservoir and connectors, depending on clinician preference and use. In practice, a catheter is implanted into the space where CSF drainage is necessary (ventricles of the brain or lumbar subarachnoid space) and connected to a valve. The valve is used to control the CSF drainage rate. The other side of the valve is connected to a catheter which is placed to allow drainage to the desired site, typically the right atrium of the heart or the peritoneal cavity. As needed, a clinician may also incorporate a reservoir, for a closed ventricular access site, and/or additional connectors into the shunt system.

Catheters are silicone elastomer and some models are made from high durometer silicone elastomer. Valve mechanisms are categorized as diaphragm and miter. For diaphragm valves, the mechanism is an umbrella shaped component oriented at right angles to the flow path. Miter valves incorporates two silicone flaps in the shape of a duckbill. The flaps part in response to a pressure differential to allow flow. Some vales are available with low, medium or high closing pressure ranges and some contain an anti-siphon component. Reservoirs are available as standard or side-inlet or convertible and in various sizes; some have an on-off flushing feature. A variety of connectors, made of nylon or silicone elastomer material, are also available.

The provided text describes a 510(k) summary for Integra Neurological Shunts and Accessories. The summary focuses on establishing substantial equivalence to previously marketed devices, particularly regarding the addition of MRI safety information.

Here's an analysis of the acceptance criteria and the study that proves the device meets them, based on the provided text:

Focus of the Study: MRI Safety Information

The key aspect of the study described is the demonstration of MRI safety for the Integra Neurological Shunts and Accessories. The acceptance criteria and testing are designed to support an "MR Conditional" claim on the device labeling.

1. Table of Acceptance Criteria and Reported Device Performance

2. Sample Size Used for the Test Set and Data Provenance

The text does not specify a numerical "sample size" in terms of number of individual devices tested. It refers to "the devices" or "all tested implants" for the RF Heating Test, implying that representative samples of the various Integra Neurological Shunts and Accessories products listed were tested. The data provenance is described as non-clinical testing performed by the applicant, Integra LifeSciences Corporation, in a laboratory setting to demonstrate MRI compatibility. There is no mention of country of origin of data or retrospective/prospective clinical data for these specific tests, as they are engineering/physical property tests.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of those Experts

This type of information is not applicable to the non-clinical engineering tests performed for MRI safety. Ground truth in this context is established by the physical laws and measurement protocols defined by the ASTM standards.

4. Adjudication Method for the Test Set

This is not applicable. The data from these tests are quantitative measurements against predefined criteria, not subjective assessments requiring adjudication.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

This is not applicable. The document describes non-clinical engineering tests related to MRI safety, not a clinical study involving human readers or AI.

6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) was done

This is not applicable. The device is a physical medical device (shunts and accessories), not an algorithm or AI software. Therefore, there is no "standalone algorithm" performance to report.

7. The Type of Ground Truth Used

The ground truth for these non-clinical tests is based on:

• ASTM Standard Operating Procedures and Definitions: For displacement force (ASTM F2052-06e1), torque (ASTM F2213-06), and RF heating (ASTM F2182-09). These standards define how the measurements are taken and what constitutes safe limits.
• Physical Properties: The inherent physical response of the device materials to magnetic fields and radiofrequency energy.

There is no "expert consensus," "pathology," or "outcomes data" used as ground truth for these MRI safety tests.

8. The Sample Size for the Training Set

This is not applicable. There is no training set mentioned or implied, as the described tests are non-clinical hardware evaluation, not a machine learning model development.

9. How the Ground Truth for the Training Set was Established

This is not applicable for the same reason as point 8.

Ask a specific question about this device